Get the Stockscreener App
0.89
0.00%
0.00
Neurosense Therapeutics Ltd stock is traded at $0.89, with a volume of 152.20K.
It is up +0.00% in the last 24 hours and down -5.33% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$0.89
Open:
$0.8995
24h Volume:
152.20K
Relative Volume:
0.45
Market Cap:
$26.43M
Revenue:
-
Net Income/Loss:
$-10.21M
P/E Ratio:
-1.5235
EPS:
-0.5842
Net Cash Flow:
-
1W Performance:
-23.93%
1M Performance:
-5.33%
6M Performance:
-62.61%
1Y Performance:
-4.30%
1-Day Range:
$0.86
$0.8995
1-Week Range:
$0.86
$1.0999
52-Week Range:
$0.81
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.89 | 26.43M | 0 | -10.21M | 0 | -0.5842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
Wall Street Zen Downgrades NeuroSense Therapeutics (NASDAQ:NRSN) to Sell - Defense World
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
A better buy-in window may exist right now for Lexicon Pharmaceuticals Inc (LXRX) - setenews.com
NRSN: PARAGON phase III ALS trial starts mid-2026, with strong data, FDA clearance, and global scope - TradingView — Track All Markets
NRSN: Global phase III ALS trial set for mid-2026, with strong efficacy and active partnership talks - TradingView — Track All Markets
NeuroSense Completes Data Collection for Alzheimer’s Trial - TipRanks
NeuroSense (NRSN) locks RoAD Phase 2 Alzheimer’s trial database, eyes Q1 2026 data - Stock Titan
NeuroSense completes data collection for Alzheimer’s trial - MSN
Will NeuroSense Therapeutics Ltd. (H1Z) stock outperform value peersEarnings Summary Report & Daily Oversold Stock Bounce Ideas - Newser
How strong is NeuroSense Therapeutics Ltd. Equity Warrant stock balance sheetMarket Performance Report & Verified Short-Term Trading Plans - Newser
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 - Nasdaq
NeuroSense Therapeutics LtdResuming regulatory advancement in Canada for PrimeC in amyotrophic lateral sclerosis - marketscreener.com
NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug - TipRanks
Neurosense Therapeutics LtdResuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis - TradingView
NeuroSense (NASDAQ: NRSN) plans April 2026 Health Canada pre-NDS as it eyes mid-2026 NDS - Stock Titan
Is NeuroSense Therapeutics Ltd. stock overvalued by current metricsMarket Growth Review & Capital Protection Trading Alerts - Newser
How interest rate cuts could boost NeuroSense Therapeutics Ltd. Equity Warrant stockWeekly Trade Summary & AI Enhanced Trade Execution Alerts - Newser
NeuroSense Therapeutics (NRSN) Stock Analysis Report | Financials & Insights - Benzinga
What downside risks could hit NeuroSense Therapeutics Ltd. (H1Z) stockPortfolio Value Summary & Risk Managed Investment Signals - Newser
Aug EndMonth: How NeuroSense Therapeutics Ltd stock compares to growth peersWeekly Investment Report & Risk Managed Investment Strategies - BỘ NỘI VỤ
Is NeuroSense Therapeutics Ltd H1Z a good long term investmentMean Reversion Trades & High Return Capital Strategies - earlytimes.in
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers (PR Newswire) - Aktiellt
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community (PR Newswire) - Aktiellt
Hedge Fund Moves: How NeuroSense Therapeutics Ltd. stock compares to growth peers2025 Bull vs Bear & Proven Capital Preservation Methods - moha.gov.vn
NeuroSense Therapeutics (NASDAQ:NRSN) Given “Buy” Rating at D. Boral Capital - Defense World
NeuroSense Gains FDA Approval for Phase 3 ALS Trial - MSN
Prepare Yourself for Liftoff: NeuroSense Therapeutics Ltd (NRSN) - setenews.com
D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq
NeuroSense receives FDA clearance to initiate pivotal phase 3 trial for PrimeC in ALS - marketscreener.com
NeuroSense Therapeutics (NRSN) Maintains 'Buy' Rating and $14 Ta - GuruFocus
NeuroSense Therapeutics Cleared by FDA to Initiate Phase 3 Trial for PrimeC to Treat ALS - marketscreener.com
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS - Barchart.com
NeuroSense Therapeutics Ltd. (NRSN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can NeuroSense Therapeutics Ltd. (H1Z) stock ride next bull market cyclePortfolio Value Summary & AI Forecasted Stock Moves - newser.com
NeuroSense Therapeutics Schedules Shareholder Meeting to Approve Equity Compensation - TipRanks
Can NeuroSense Therapeutics Ltd. stock hit analyst price targetsQuarterly Portfolio Summary & Free Real-Time Volume Trigger Notifications - newser.com
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer) | NRSN SEC FilingForm 6-K - Stock Titan
Is NeuroSense Therapeutics Ltd. (H1Z) stock a safe buy pre earningsWatch List & Consistent Growth Equity Picks - newser.com
Will NeuroSense Therapeutics Ltd. (H1Z) stock beat revenue estimatesDip Buying & Free Reliable Trade Execution Plans - newser.com
How strong dollar benefits NeuroSense Therapeutics Ltd. (H1Z) stockJuly 2025 Final Week & Expert Approved Trade Ideas - newser.com
Using RSI to spot recovery in NeuroSense Therapeutics Ltd.IPO Watch & Weekly Top Stock Performers List - newser.com
What risks investors should watch in NeuroSense Therapeutics Ltd. Equity Warrant stockQuarterly Portfolio Review & Low Volatility Stock Suggestions - newser.com
Why NeuroSense Therapeutics Ltd. stock is in analyst buy zoneJuly 2025 Retail & Free Safe Entry Trade Signal Reports - newser.com
Key metrics from NeuroSense Therapeutics Ltd. Equity Warrant’s quarterly data2025 Geopolitical Influence & Advanced Swing Trade Entry Plans - newser.com
What sentiment indicators say about NeuroSense Therapeutics Ltd. stockQuarterly Portfolio Review & High Conviction Trade Alerts - newser.com
Is NeuroSense Therapeutics Ltd. stock a bargain at current levels - newser.com
Will NeuroSense Therapeutics Ltd. (H1Z) stock sustain uptrend momentumWeekly Earnings Recap & Weekly Return Optimization Alerts - newser.com
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):